In Depth 26 Jan 2024
Long COVID: are we on the verge of a breakthrough?
Studies and recent developments in long COVID research could pave the way for more diagnostic and therapeutic opportunities.
In Depth
- Latest Posts
In Depth 25 Jan 2024
The trends that will shape the biotech industry in 2024
What does 2024 hold for the biotech industry? Delve into the experts’ insight on the biotech trends that will shape 2024.
In Depth 24 Jan 2024
A new chapter in cell therapy: engineered B cells reach the clinic for the first time
Cell therapy has drastically improved the scope of treatment for a number of diseases in the last few years. Now, engineered B cells are the latest approach in the field of cell therapy, having recently made it into clinical trials. But what exactly are B cells and how can they be engineered to treat diseases? […]
In Depth 19 Jan 2024
Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?
Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases.
In Depth 18 Jan 2024
GLP-1 agonists: what’s the hype about?
GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs.
In Depth 17 Jan 2024
Bladder cancer treatment: where are we standing?
Bladder cancer is the 10th most common cancer. Delve into the most promising strides in bladder cancer treatment.
ADVERTISEMENT
ADVERTISEMENT
In Depth 15 Jan 2024
The future of diabetes treatment: Is a cure possible?
Diabetes has become an epidemic. Science is striving to find a diabetes treatment that can cure this chronic disease, but how close are we?
In Depth 10 Jan 2024
The biggest private biotech investments in December 2023
The companies Tome Biosciences, Bicara Therapeutics, and Seismic Therapeutic bagged the biggest biotech investments in December 2023. Around the world, food, immunology, oncology, central nervous system (CNS), and biofermentation players attracted the biggest funding rounds overall. Although December is generally a quiet time for biotech fundraising, there were still some big rounds raised in the […]
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
In Depth 13 Dec 2023
Revolutionizing glioblastoma treatment: how CAR-T cell therapy could be used as a cure
Find out how CAR-T cell therapy, which has been so groundbreaking in treating blood cancers, could be used to cure glioblastoma.
In Depth 11 Dec 2023
European patents in biotech: how to prevent invalid patents?
The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process is complex but essential. As […]
In Depth 7 Dec 2023
The biggest private biotech investments in November 2023
The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […]
ADVERTISEMENT
